InvestorsHub Logo
Followers 3
Posts 582
Boards Moderated 0
Alias Born 01/19/2012

Re: None

Sunday, 05/20/2018 10:38:34 PM

Sunday, May 20, 2018 10:38:34 PM

Post# of 7807
Our Pipeline Evolution
10 NME filings 2015-2019, each with $1B+ potential
sirukumab Rheumatoid arthritis
fulranumab Osteoarthritic pain
daratumumab Multiple myeloma
esketamine Treatment resistant depression
guselkumab Psoriasis
apalutamide
(ARN-509) Pre-metastatic prostate cancer
lumicitabine
(JNJ-1575) RSV infections
erdafitinib
(FGFR inhibitor) Solid tumors
imetelstat Myelofibrosis
AL-335 HCV
Our Pipeline Evolution
JNJ-7922
http://files.shareholder.com/downloads/JNJ/0x0x943362/5ED20A6F-9534-4698-81E8-80A78BDD0285/William_Hait_Slides.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GERN News